Expert Interview
Discussing the Phase 2 data on BioXcel's BXCL701 in metastatic SCNC-variant castration-resistant prostate cancer
Ticker(s): BTAIInstitution: Institut Gustave Roussy
- Medical oncologist at Institut Gustave Roussy, Professor of Oncology at the University of Paris Saclay in Villejuif, France & Founder of the Prostate Cancer Consortium (PEACE) in Europe.
- Manages over 100 patients with prostate cancer.
- Involved in many practice-changing phase I -III clinical trials in advanced prostate cancer including GETUG 12, GETUG 13, TAK700 post-docetaxel trials, where he is the global/national coordinating investigator.
Can you please tell us more about your approach towards treating small cell neuroendocrine metastatic castration-resistant prostate cancer?
Added By: slingshot_insightsWhat is the mechanism of action of the BXCL701 + KEYTRUDA combination treatment?
What is the efficacy of BXCL701 + KEYTRUDA in treating small cell neuroendocrine metastatic castration-resistant prostate cancer?
What are the potential side effects of BXCL701 + KEYTRUDA ?
Added By: slingshot_insightsHow does the BXCL701 + KEYTRUDA combo compare to other treatments you’re experienced with?
Could you please discuss the trial results for BXCL701 + KEYTRUDA available to date?
How does BXCL701 + KEYTRUDA compare to other treatment options, in terms of the cost?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
